Data – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Mon, 30 Aug 2021 11:45:43 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Big Data and AI Can Guide Cannabis Medicine https://mjshareholders.com/big-data-and-ai-can-guide-cannabis-medicine/ Mon, 30 Aug 2021 11:45:43 +0000 https://www.cannabisfn.com/?p=2932074

Robin Lefferts

August 30th, 2021

App, Exclusive, News, Top Story


In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived medicines for approval.

In order for those things to happen, robust data around the efficacy of cannabis treatments needs to be gathered and widely understood. In the meantime, cannabis patients and providers are often stuck with a personal trial-and-error approach to finding the right treatment for their own needs. RYAH Group Inc. (CSE: RYAH) is one company that is pushing forward in all of these areas. The company’s smart delivery devices, database with over 200,000 users, and artificial intelligence-powered data engine combine to form a powerful Internet of Things solution with the potential to more fully legitimize cannabis medicine while making it more effective for current patients.

Moving the Industry Forward

Regulators like the United States Food and Drug Administration (FDA) need data to make informed decisions. Big pharma companies need data to even undertake research programs aimed at developing new potential drugs. Doctors need data to feel comfortable giving prescriptions or recommendations for treatment.

Since the cannabis industry is so young, was prohibited for so long, and still faces a myriad of patchwork and inconsistent regulations, cannabis medicine is severely lacking the large datasets that are crucial for the industry’s development. In this regard, RYAH is well-positioned to provide all interested parties with the information necessary for growth and advancement.

RYAH’s Data Sharing Benefits

The company’s smart devices and data solutions are gaining traction with cannabis researchers across the globe. The controlled dosing, easily recorded personal feedback from patients, wealth of data stored in RYAH’s Cloud database, and AI-powered data interpretation and organization give researchers tools that make their studies more effective and efficient. RYAH is involved in trials and studies in Britain, Italy, Italy again, and the Channel Islands. The company also has deals in France and New Zealand for distribution and potential inclusion in clinical trials and major studies.

RYAH’s goal is to provide regulators, researchers, and drug companies all the data they need to mainstream plant-based medicine, and it looks like the company is on its way.

Click here to receive an investor presentation and corporate updates

Improving the Patient Experience

RYAH’s smart devices, connected apps, and AI data interpreter can help patients and doctors effectively hone a treatment regimen according to the patient’s own feedback combined with that of the other users in the system. Without the insights from a large patient pool and the ability to easily record, track, and interpret personal experiences and preferences, many cannabis patients can get a little lost. Which strain? What is the proper dose? Has this particular type of treatment worked for other people?

Watch how Ryah technology Benefits to Patients and Doctors

RYAH’s system offers control and assurance, not only to researchers and patients involved in clinical trial programs but also to normal, everyday medical cannabis users in search of a little guidance. To many, using cannabis presents a great unknown fraught with risks. RYAH helps to alleviate those concerns and bring the cannabis patient experience more in line with that of conventional patients.

The Takeaway

This type of system is right in line with the larger trend toward tele-health and the use of machine learning and artificial intelligence to improve patient outcomes. Overall, the market for remote treatment is growing at a 26.5% CAGR, expected to reach $475 billion in the next five years. It’s a huge trend in healthcare, and RYAH is at the forefront of the movement in the cannabis industry.

The two aspects of RYAH’s business go hand in hand, improving treatments for cannabis patients while providing data and a platform that enables research and regulation that will further legitimize the industry as a whole. Keep an eye out for continued developments in the RYAH story.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.


]]>
RYAH Group Ships Devices for Use in Pilot Program with Medicann in Jersey, Channel Islands https://mjshareholders.com/ryah-group-ships-devices-for-use-in-pilot-program-with-medicann-in-jersey-channel-islands/ Wed, 23 Jun 2021 14:06:11 +0000 https://www.cannabisfn.com/?p=2923363

Ryan Allway

June 23rd, 2021

News, Top News


TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — RYAH Group, Inc. (CSE:RYAH) (“RYAH” or the “Company”) today announces that it has completed an initial shipment of its proprietary RYAH Smart Dry Herb Inhalers for use in a pilot study to be conducted by Medicann in Jersey, the largest of the Channel Islands, located between England and France. Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. Medicann is launching an observational study using RYAH Smart Dry Herb Inhalers in order to collect patient feedback on consumption of cannabis strains available on the Island, including strains supplied by Aurora Europe, a subsidiary of Canadian-headquartered Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives.

In addition to the pilot program, the parties are working toward an exclusive, definitive supply and distribution agreement, which, if entered into, is expected to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in the region.

Jersey, Channel Islands, which is known to have one of the highest GDP per capita in the world, is a British dependency island ideally situated in the English Channel off the coast of France. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 billion.

By 2024, the medicinal cannabis market within the United Kingdom is predicted to be worth nearly US$1.3 billion, servicing nearly 340,000 active patients. According to a report by the United Nations International Narcotics Control Board, the U.K. has emerged as the largest supplier of medicinal cannabis in the world. The European cannabis market is forecast to grow with a compound annual growth rate (CAGR) of 67.4% to reach 3.2 billion euros ($3.75 billion) by 2025.

“We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. RYAH is pleased to contribute RYAH’s IoT devices and data platform and work with Medicann toward perfecting prescribing practices and dosing regimens,” said Gregory Wagner, CEO of RYAH Group, Inc.

About RYAH Group, Inc.

RYAH Group, Inc. (“RYAH”) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (LPs) to monitor and manage formulation effects on patients and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Forward-Looking Statements

This press release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements“). All statements contained in this press release that are not statements of historical fact should be considered forward-looking statements. Forward looking statements are often identified by terms such as “may,” “should,” “anticipate,” “expect,” “potential,” “believe,” “intend” or the negative of these terms and similar expressions. Specifically, forward-looking statements in this press release include, but are not limited to, statements related to (i) the pilot study to be conducted by Medicann in Jersey using RYAH Smart Dry Herb Inhalers; (ii) the Company and Medicann’s efforts to negotiate and enter into an exclusive definitive supply and distribution agreement to position Medicann as the sole supplier and distributor of the RYAH Smart Dry Herb Inhalers in Jersey; and (iii) the anticipated size and growth of the recreational and/or medicinal cannabis market within the United Kingdom and Europe. Forward-looking statements reflect the Company’s current views and intentions with respect to future events based on current information available to the Company and are necessarily subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with or inherent in (i) the general business and economic conditions in the regions in which the Company operates; (ii) the expected benefits of the Company’s product offerings and the anticipated results and experience of users thereof; (iii) the Company’s ability to execute on key priorities, implement business strategies and/or pursue business opportunities; (iv) disruptions in or attacks (including cyberattacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; (v) changes to, or the application of, laws and regulations; and (vi) such other factors set out in the Company’s public disclosure documents available under the Company’s profile on SEDAR at www.sedar.com. Readers are further cautioned that the assumptions used in the preparation of such forward-looking statements (including, but not limited to, the assumption that (i) the Company will be able to execute on its business plan and will obtain and maintain all necessary permits and authorizations to execute on its business plan; (ii) the Company’s financial condition and development plans do not change as a result of unforeseen events; (iii) there will continue to be a demand, and market opportunity, for the Company’s product offerings; (iv) the Company will be able to establish, preserve and develop its brand and attract and retain required personnel; (v) current and future economic conditions will neither affect the business and operations of the Company nor the Company’s ability to capitalize on anticipated business opportunities; (vi) Medicann will undertake and complete the pilot study in Jersey upon the terms anticipated by the Company; (vii) there will continue to be a viable business opportunity for Medicann and the Company to work together; and (viii) the Company will be able to secure capital and financing on acceptable terms), although considered reasonable by management of the Company at the time of preparation, may prove to be imprecise and result in actual results differing materially from those anticipated, and, as such, undue reliance should not be placed on forward-looking statements. Should any such risk factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur.

The forward-looking statements included in this press release are made as of the date of this press release, and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. All forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

This press release includes market and industry data that has been obtained from third-party sources, including industry publications. The Company believes that the industry data is accurate and that its estimates and assumptions are reasonable, but there can be no assurance as to the accuracy or completeness of this data. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release or ascertained the underlying economic assumptions relied upon by such sources.

Neither the Canadian Securities Exchange (“CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For additional information, please contact:

Sofiya Kleshchuk
Client Relations
+1 917 210 0543
[email protected]

Gregory Wagner, CEO
+1 917 210 0543
[email protected]

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
BLOCKStrain: Three Target Markets, One Breakthrough Platform https://mjshareholders.com/blockstrain-three-target-markets-one-breakthrough-platform/ Tue, 19 Mar 2019 20:00:09 +0000 https://www.cannabisfn.com/?p=2326222

Ryan Allway

March 19th, 2019

Exclusive, News, Top News


The global cannabis industry is projected to reach nearly $150 billion by 2025, according to Grand View Research, as a growing number of governments legalize marijuana. While legalization has created an overnight multi-billion dollar market for investors, consumers, cultivators, and regulators have struggled to build regulations around such a rapidly growing industry, and that has created numerous challenges across the value chain.

BLOCKStrain Technology Corp. (TSX-V: DNAX) (OTC: BKKSF) has created the world’s first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry. In doing so, the company solves many of the challenges facing consumers, retailers, cultivators, and regulators. Investors may want to keep a close eye on the company given its early traction in North America and broad appeal to multiple parts of the industry.

[embedded content]

Consumers & Retailers

Cannabis consumers have very little information about how certain cannabis strains will affect their body. Even worse, microbial or chemical contamination can make some cannabis outright dangerous for human consumption. There’s no way for consumers to be truly confident in their purchases—they must usually trust the brand or dispensary. Similarly, dispensaries must trust cultivators when they purchase their inventory.

BLOCKStrain’s data and certification system gives consumers the information they need to make informed decisions about the products that they purchase. Using a QR code, consumers can track the path the product has taken to retail shelves, along with the cannabinoid and terpene profiles needed to make smart decisions. They can also be confident that the product is chemically-pure and free of pesticides and molds.

For retailers and distributors, BLOCKStrain helps protect reputations by ensuring that 100% of the product going to retail has passed through all of the correct testing and screening processes. The BLOCKStrain Seal is quickly being adopted as the single source of trust for consumers, and by stocking shelves with verified products, you can inspire confidence in customers and ensure that they keep returning again and again.

Cultivators & Licensed Producers

Cannabis is a complex plant with over 400 properties that differ between strains, depending on the seed, fiber, cannabinoid content, regional or cultivation environments, growth characteristics, flavor, or terpene profile. While patents can help protect strain-related intellectual property on a theoretical level, it can be difficult to license strains to other cultivators without the risk of them cloning the plant and selling it as their own.

BLOCKStrain’s platform enables cultivators to release their varieties into the public domain without fear of losing their ownership claim or rights to be paid for intellectual property. They can easily manage and share the history of a clone, as well as the data collected during its grow cycle. In addition, the technology eases the burden of collecting and reporting administrative data to conserve resources and ensure accuracy.

For example, the company recently signed a validation testing program agreement with Harvest One Cannabis Inc. (TSX-V: HVT) (OTCQX: HRVOF), a Canadian licensed producer of medical cannabis, to deploy its proprietary genome tracking software to collect and register its cannabis plant DNA and strains. The move comes after the company signed a similar agreement with WeedMD Inc. (TSX-V: WMD), another licensed producer in Canada.

Government Regulators

The cannabis industry is desperately seeking legitimacy as it moves from the illicit black market to a legalized market across a growing number of jurisdictions. Like any other consumer product, it’s only through the full faith and trust of government regulation that consumers will trust the product. The challenge for regulators is coming up with and implementing controls to ensure that products are tested and verified.

BLOCKStrain leverages immutable and secure blockchain technology, as well as proprietary track-and-trace software, to provide the validation and verification that governments require. Governments are choosing BLOCKStrain as the backbone of certification, verification, consumer reporting, and the monitoring of federally-regulated reporting. The technology is a leap forward in legitimizing the industry and ensuring compliance.

Looking Ahead

BLOCKStrain Technology Corp. (TSX-V: DNAX) (OTC: BKKSF) addresses multiple parts of the cannabis value chain, making it a cornerstone technology in compliance and quality control. Investors interested in ancillary parts of the cannabis industry may want to take a closer look at the company following its recent deal with WeedMD Inc. (TSX-V: WMD), where it rolled out the industry’s first cannabis strain validation program in Canada’s mature market.

The company’s stock also became easier to purchase in the United States after securing DTC eligibility in late February. With improved settlement for its shares, U.S. investors can easily participate in the company’s growth story via a wide range of brokers.

For more information, visit the company’s website at www.blockstrain.io.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>